New Data Analyses from Phase 3 Study of Investigational Gene Therapy Nadofaragene Firadenovec Presented at Society of Urologic Oncology Annual Meeting Adds More Evidence to Data Published in Lancet Oncology Low rate of cystectomy and delayed time to cystectomy among...
Landmark Study in Non-Muscle Invasive Bladder Cancer Evaluating Breakthrough Investigational Gene Therapy Nadofaragene Firadenovec Published in The Lancet Oncology Novel intravesical gene therapy given once every three months studied in patients with high-grade,...
Gene therapy company focused on uro-oncology continues to expand operations and prepare for the future commercialization of an investigational treatment for non-muscle invasive bladder cancer CAMBRIDGE (June 17, 2020) – FerGene, Inc., a privately held gene therapy...
The U.S. Food and Drug Administration (FDA) has issued a response to the Biologics License Application (BLA) for investigational gene therapy, nadofaragene firadenovec, which was submitted by FKD Therapies Oy, the company leading the development and regulatory filing...
Data highlight a need for bladder-sparing therapies to improve outcomes for patients with high-grade, non-muscle invasive bladder cancer CAMBRIDGE, Mass. – February 10, 2020 FerGene, a newly created gene therapy company committed to revolutionizing the treatment...
Recent Comments